The Cystic Fibrosis National Resource Centers provide study sponsors and investigators centralized expertise in
Site Search
The Cystic Fibrosis Foundation offers a broad range of funding opportunities to support academic and industry investigators to pursue research on topics relevant to cystic fibrosis. Each application undergoes a rigorous scientific review process before funding is allocated.
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
Through efficient study design, optimized clinical trial execution, and high-quality data, the Therapeutics Development Network (TDN) helps speed the delivery of new and better therapies to people with cystic fibrosis.
Postdoctoral research fellowship awards are offered to MDs, PhDs, and MD/PhDs who are interested in conducting basic research related to cystic fibrosis.
This program supports research that will accelerate the discovery and development of therapies to restore cystic fibrosis transmembrane conductance regulator (CFTR) function in all patients with cystic fibrosis.
Research grants are intended to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis.
Pilot and feasibility awards are intended to support basic science research studies focused on developing and testing new hypotheses in areas relevant to cystic fibrosis.
The Cystic Fibrosis Foundation regularly assesses its key research priorities to ensure we are on track to accomplish our mission to cure CF and to provide people with CF the opportunity to lead long lives. Applicants are encouraged to align submissions to these priorities to maximize their potential for being funded.
Since the launch of the Infection Research Initiative in 2018, the Cystic Fibrosis Foundation has funded more than $100 million in research to improve the detection, diagnosis, treatment, and outcomes of CF-related infections.